Maharashtra FDA Targets Bollywood Stars Over Vimal Ad
The Maharashtra Food and Drug Administration has moved beyond show‑cause notices and started proceedings against Bollywood actors Shah Rukh Khan, Ajay Devgn and Tiger Shroff for their appearance in a Vimal Elaichi advertisement. Commissioner Tukaram Mundhe clarified that the actors are treated as a…
By Felo News Desk · Published
The Maharashtra Food and Drug Administration (FDA) has officially moved the Vimal Elaichi controversy from the show‑cause notice stage to formal proceedings, marking a significant escalation in the case against three of India’s biggest film stars. The actors—Shah Rukh Khan, Ajay Devgn and Tiger Shroff—had appeared in a television advertisement for Vimal Elaichi, a product that the FDA claims is a surrogate for Vimal Pan Masala, a tobacco‑based smokeless product banned in the state.
What the FDA Allegations Are About
On 11 August, the FDA issued show‑cause notices to the three actors, citing Sections 24 and 53 of the Food Safety and Standards Act. Section 24 deals with misleading advertisements, while Section 53 allows the department to impose penalties of up to ₹10 lakh for publishing or being part of a misleading food advertisement. The notices demanded that the actors explain why they participated in a campaign that could be interpreted as promoting a prohibited product.
Commissioner Tukaram Mundhe’s Clarification
Commissioner Tukaram Mundhe explained in an interview with NDTV that the actors’ celebrity status does not exempt them from the law. “According to you they may be stars, but according to me they are only advertisers in this case,” he said. “I am looking at them as violators of the law, and the law will take its own course.” The FDA is therefore treating the actors as ordinary advertisers, holding them accountable for the content they endorse.
Mundhe also highlighted that the responsibility for an advertisement lies with the person or institution that carries it out. “Advertisers are expected to carry out due diligence before associating themselves with a product or campaign,” he added, underscoring that endorsers cannot simply shift blame to the manufacturer.
Current Status of the Proceedings
According to the commissioner, one of the three actors has not responded to the show‑cause notice, and formal adjudication and prosecution have already begun in that case. The other two actors have submitted responses, which the FDA will now review as part of the legal process. While Mundhe could not confirm the exact status of Shah Rukh Khan’s reply, he indicated that the information would be available through the assistant commissioner’s office.
The next steps will involve determining how each actor’s response is treated and whether further penalties or actions are warranted. The FDA’s approach is consistent with its mandate to enforce food safety laws and to curb surrogate advertising of banned products.
Why This Matters for Bollywood and Public Health
Surrogate advertising—using celebrities or other influencers to promote prohibited products—has long been a concern for regulators in India. By treating actors as advertisers, the FDA is sending a clear message that fame does not grant immunity from legal scrutiny. This case could set a precedent for how the industry handles endorsements of restricted or harmful products.
For consumers, the move underscores the importance of regulatory oversight in protecting public health, especially in regions where tobacco and smokeless products remain a major health issue. The FDA’s actions aim to deter future promotions that could mislead the public about the safety or legality of such products.
What to Watch Next
The proceedings will likely culminate in a formal decision by the FDA, which may include fines or other sanctions against the actors if they are found in violation of the Food Safety and Standards Act. The case will also be closely monitored by industry stakeholders, who may reassess their endorsement strategies to avoid similar legal challenges.
As the legal process unfolds, the public and the film industry will be watching to see whether the FDA’s stance will influence future advertising practices and whether it will deter the use of celebrity endorsements for prohibited products.
Key facts
- Maharashtra FDA has moved from show‑cause notices to formal proceedings against three Bollywood stars.
- Commissioner Mundhe treats the actors as ordinary advertisers, not celebrities, under the law.
- One actor has already faced adjudication; the others have submitted responses.
- Surrogate advertising of banned products is a key regulatory concern in India.
- The case may set a precedent for future celebrity endorsements of restricted items.
Why it matters
The case highlights how regulatory bodies are enforcing food safety laws against high‑profile individuals, potentially reshaping endorsement practices in India’s entertainment industry.
Frequently asked questions
What is surrogate advertising?
Surrogate advertising is a marketing strategy where a brand uses a third party, such as a celebrity or influencer, to promote a product indirectly, often to circumvent advertising restrictions.
What penalties can the FDA impose?
Under Section 53 of the Food Safety and Standards Act, the FDA can impose penalties of up to ₹10 lakh for publishing or being part of a misleading food advertisement.
Will the actors face fines?
If the FDA finds them in violation of the Act, they could be subject to fines or other sanctions, but the final decision will depend on the outcome of the proceedings.
Sources
- [1] gulfnews.com — originally reported as “‘Violators of law’: Tukaram Mundhe on Shah Rukh Khan, Ajay Devgn, Tiger Shroff over Vimal ad”
